Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Low Grade Upper Tract Urothelial Carcinoma

Conditions

Low Grade Upper Tract Urothelial Carcinoma

Trial Timeline

Dec 22, 2025 → Nov 1, 2030

NCT ID

NCT07265947

About Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD

Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBD is a phase 2 stage product being developed by Tyra Biosciences for Low Grade Upper Tract Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07265947. Target conditions include Low Grade Upper Tract Urothelial Carcinoma.

What happened to similar drugs?

0 of 7 similar drugs in Low Grade Upper Tract Urothelial Carcinoma were approved

Approved (0) Terminated (1) Active (6)

🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3

❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3

🔄rituximabBiogenPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄Remestemcel-LMesoblastPhase 3

🔄remestemcel-LMesoblastPhase 3

🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07265947	Phase 2	Recruiting	Dec 22, 2025	Nov 1, 2030	Low Grade Upper Tract Urothelial Carcinoma

Competing Products

20 competing products in Low Grade Upper Tract Urothelial Carcinoma

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
DS-1001b	Daiichi Sankyo	Phase 2	39
Rabeprazole Sodium	Eisai	Pre-clinical	26
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Abemaciclib + Letrozole	Eli Lilly	Phase 2	42
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	42
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	39
Mirvetuximab Soravtansine	AbbVie	Phase 2	42
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	42
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	35
Cilengitide	Merck	Phase 2	31
Avelumab	Merck	Phase 2	35